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Abstract
Background: A principal goal for the use of positron emission tomography (PET) in oncology is for real-time
evaluation of tumor response to chemotherapy. Given that many contemporary anti-neoplastic agents function by
impairing cellular proliferation, it is of interest to develop imaging modalities to monitor these pathways. Here we
examined the effect of capecitabine on the uptake of thymidine analogs used with PET: 3’-deoxy-3’-[18F]fluorothymidine
(18F-FLT), 1-(2’-deoxy-2’-[18F]fluoro-β-D-arabinofuranosyl) thymidine (18F-FMAU), and 1-(2’-deoxy-2’-[18F]fluoro-β-
D-arabinofuranosyl) uracil (18F-FAU) in patients with advanced cancer.
Methods: Fifteen patients were imaged, five with each imaging agent. Patients had been previously diagnosed with
breast, colorectal, gastric, and esophageal cancers and had not received therapy for at least 4 weeks prior to the first
scan, and had not been treated with any prior fluoropyrimidines. Subjects were imaged within a week before the start
of capecitabine and on the second day of treatment, after the third dose of capecitabine. Tracer uptake was quantified
by mean standard uptake value (SUVmean) and using kinetic analysis.
Results: Patients imaged with 18F-FLT showed variable changes in retention and two patients exhibited an increase in
SUVmean of 172.3 and 89.9 %, while the other patients had changes ranging from +19.4 to -25.4 %. The average change
in 18F-FMAU retention was 0.2 % (range -24.4 to 23.1) and 18F-FAU was -10.2 % (range -40.3 to 19.2). Observed changes
correlated strongly with SUVmax but not kinetic measurements.
Conclusions: This pilot study demonstrates that patients treated with capecitabine can produce a marked increase in
18F-FLT retention in some patients, which will require further study to determine if this flare is predictive of therapeutic
response. 18F-FAU and 18F-FMAU showed little change, on average, after treatment.
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Background
Capecitabine is a carbamate prodrug form of 5-
fluorouracil (5-FU), approved for the treatment of
metastatic colorectal and breast cancers, and can be
used as monotherapy or in combination with other
cytotoxic and targeted agents [1, 2]. Conversion to 5-
FU is accomplished via the action of three enzymes:
carboxylesterase, cytidine deaminase, and thymidine phos-
phorylase, the latter of which is found at higher concen-
trations in tumor cells than in normal tissue [3, 4].
Following conversion to 5-FU, anti-tumor activity is
achieved via inhibition of thymidylate synthase (TS) and
incorporation of 5-FU into RNA and DNA [4, 5]. Despite
its widespread use, additional research is needed to
explore its mechanisms of cytotoxicity, activation, metab-
olism, and to develop methods to monitor efficacy.
Due to its effects on thymidine synthesis and incorpor-
ation pathways, capecitabine may alter the uptake and
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retention of thymidine analogs used with positron emis-
sion tomography (PET) imaging and this could provide a
method for assessing response and understanding drug
pharmacodynamics. In part, this is due to increased ex-
pression of thymidine kinase 1 (TK1) in the salvage
pathway, which is involved in the uptake and utilization
of thymidine from the plasma through phosphorylation.
Increased TK1 expression in tumors has been imaged
with 11C-thymidine and thymidine analogs such as 3’-
deoxy-3’-[18F]fluorothymidine (18F-FLT) [6–8]. 18F-FLT
has been used to monitor cell proliferation [9, 10], since
after uptake by tumor nucleoside transporters, 18F-FLT
is phosphorylated by TK1, causing it to be trapped intra-
cellularly [11, 12]. Because 18F-FLT is unable to incorp-
orate into the DNA structure due to the lack of a 3’
hydroxyl, its retention principally reflects intracellular
TK1 activity [13–15]. Uptake of FLT is reproducible and
has been shown to be correlated with the proliferative
marker Ki-67 [6, 10, 16].
1-(2’-deoxy-2’-fluoro-β-D-arabinofuranosyl) thymidine
(FMAU) is another thymidine analogue that was origin-
ally introduced as an anti-viral and anti-neoplastic com-
pound, but was later abandoned due to severe toxicity
[17, 18]. More recently, FMAU has been adapted to
molecular imaging [6, 19]. A key difference between
FMAU and FLT is that FMAU has an intact 3’ hydroxyl
group and can therefore incorporate into the DNA [20].
Furthermore, FMAU is a more potent substrate for
thymidine kinase 2 (TK2), located in the mitochon-
dria, than TK1 [18]. Unlike TK1, TK2 is constitutively
expressed, with low activity in both dividing and qui-
escent cells [21, 22]. Accumulation of 18F-FMAU is
higher in tumors than most healthy tissues and preclinical
studies have shown that its uptake is enhanced in re-
sponse to conditions that produce an increase in mito-
chondrial mass such as oxidative, reductive, and energy
stress [23, 24]. In addition, low physiologic uptake of 18F-
FMAU by normal bone marrow may allow it to be useful
in the detection and monitoring of bone marrow metasta-
ses [19]. Further, the rapid clearance of 18F-FMAU from
the blood in humans (90 % cleared within 10 min), allows
for improved imaging in the pelvis compared to 18F-FLT
and shortened imaging time [19, 25].
1-(2’-deoxy-2’-fluoro-β-D-arabinofuranosyl) uracil (FAU)
is a nucleoside analog that functions as a prodrug form of
FMAU [20]. Following cellular uptake of FAU, it is phos-
phorylated to FAU monophosphate (FAU-MP) and then
converted to FMAU monophosphate (FMAU-MP) via the
action of TK1 and TS, respectively [26]. FMAU-MP is then
incorporated into DNA, resulting in cell death [27]. De-
pendence on TS for activation was designed to target FAU
against malignancies with high expression of this enzyme
and to avoid the neurotoxicity that resulted in the dis-
continuation of clinical FMAU use [17, 28–30]. High
expression of TS is a major mechanism of resistance to
chemotherapeutic agents such as 5-FU and capecitabine
and has been associated with poor clinical outcome in
breast and colorectal cancer [31–33]. Furthermore, the
structure of FAU allows for its tissue distribution to be
monitored using PET, and potentially serve as a technique
for imaging the de novo TdR synthesis pathway [34, 35]. To
that end, studies of 18F-FAU in humans and dogs found
have found higher uptake in tumors than normal tissue
[28, 29]. More recently, a pharmacokinetic modeling study
demonstrated that the conversion of FAU to FMAU
is greatly increased in tumors compared to normal
tissues [36]. Although its clinical use was discontin-
ued due to hepatoxicity, FAU may have some utility
as an imaging agent.
The purpose of this study was to monitor the reten-
tion of radiolabeled fluoropyrimidines: 18F-FLT, 18F-
FMAU, and 18F-FAU in patients with breast and gastro-
intestinal cancers who received capecitabine. Given the
differences in metabolism for each of the tracers, the
effects of capecitabine were expected to vary. The
primary objective was to monitor changes in tracer
uptake as measured by mean standardized uptake value
(SUVmean) along with kinetic parameters. These parame-
ters may provide an approximation of the physiological
effect of capecitabine on tumors.
Methods
Radiochemistry and patient imaging
PET tracers were synthesized as previously published
and patients were injected intravenously with 18F-FLT
(range, 347–389 MBq; mean 372 MBq), 18F-FAU (range,
211–396 MBq; mean 346 MBq), or 18F-FMAU (range,
191–388 MBq; mean 339 MBq) over 60s as described
[25, 37, 38]. Subjects underwent dynamic PET with a
series of timed images (4×20s, 4×40s, 4×60s, and
4×180s). In patients injected with 18F-FLT and 18F-FAU,
but not 18F-FMAU, an additional series of images
was collected (8x300s). PET was conducted with a
15-cm field of view over the area of the tumors
(neck, thorax, or abdomen) followed by a whole body
image using an Exact/HR tomograph (Siemens Medical
Solutions, Malvern, Pennsylvania, USA).
Fifteen patients with solid tumors were imaged, five
with each of the fluorine-18 labeled PET tracers.
Patient accrual alternated between the three agents
based primarily on tracer availability. Malignancies
included were breast, colorectal, gastric, and esophageal
cancers (Table 1; Additional file 1: Table S1). Patients
had not received therapy for at least 4 weeks prior to
the first PET scan, and had not been previously treated
with 5-FU, capecitabine or other fluoropyrimidines. Six of
the 15 patients studied received capecitabine alone. Other
patients were placed on standard regimens, which utilized
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radiotherapy and oxaliplatin as well as targeted agents
such as lapatinib, bevacizumab, and trastuzumab (Table 1).
When capecitabine was combined with other treatments
they were started after the third dose of capecitabine and
after completion of the final PET scan. Patients underwent
imaging within one week before therapy, and again one
day after the start of therapy, after receiving three doses of
capecitabine. The mean time between scans was 3.7 days
(range 2–7 days).
Patient images were analyzed with PMOD (Zurich,
Switzerland) software and regions of interest (ROIs)
were defined in a semi-automated fashion as published
[19]. ROIs were chosen in the three adjacent planes
with the highest activity, using isocontours halfway be-
tween the minimum and maximum thresholds of the
tumor. Tracer uptake was measured by standardized
uptake value (SUV). Mean SUVs (SUVmean) were calcu-
lated on whole ROIs, and maximum SUVs (SUVmax)
were measured as the pixels with the most activity in
the same ROIs.
Kinetic analysis
Kinetic modeling was conducted using PMOD (Zurich,
Switzerland) software as has been published previously
[39]. In short, 18F-FLT and 18F-FAU time-activity curves
were fitted using a 3-compartment model, which pro-
duced rate constants K1, k2, and k3. K1 (mL/g/min) rep-
resents the unidirectional transport of tracer from blood
into tissue, k2 (min−1) represents the reverse transport,
and k3 (min−1) characterizes phosphorylation and intra-
cellular trapping via thymidine kinase-1 activity. The
flux values for 18F-FLT and 18F-FAU were then calcu-
lated as K1 x k3/(k2 + k3). Tumor uptake values and
blood tissue kinetics were interpreted with respect to the
blood activity level, obtained from measurements of
tracer activity within great vessels.
For 18F-FMAU kinetic analysis, we utilized tumor re-
tention ratio (TRR), which has been shown to correlate
strongly with compartmental-K. TRR was obtained by
dividing the tumor 18F-FMAU activity—obtained in an
image from 5 to 11 min post-injection—area under the
curve (AUC) by of 18F-FMAU blood activity AUC. AUC
values were calculated using GraphPad Prism version 6
(GraphPad Software, La Jolla, California, USA), which
measures AUC using the trapezoid method. To reduce
image noise, the first 5 min were omitted. Furthermore,
we have previously shown that in 18F-FMAU blood ac-
tivity decreases sharply in the first 11 min after injection,
and that images taken within the 5–11 window are com-
parable to images from 50–60 min [19].
Statistical considerations
The relationship of one PET parameter to another was
measured using linear regression models, and the good-
ness of fit of these models was assessed using the r2
value. Regression models were fit and assessed using




Five patients (median age: 62) with breast, esophageal,
and colorectal carcinomas were imaged with 18F-FLT at
baseline, and then following capecitabine therapy. In
addition to capecitabine, 4/5 patients underwent other
anti-neoplastic therapy including: oxaliplatin, irinotecan,
Table 1 Clinical patient characteristics
Patient no. Age Sex Tumor type Other therapy with initial capecitabine Imaging tracer
1 47 F Breast Lapatinib 18F-FLT
2 65 F Breast None
3 62 F Esophageal Radiation
4 62 F Colorectal Bevacizumab, Oxaliplatin
5 56 F Colorectal Oxaliplatin
6 63 F Breast None 18F-FMAU
7 52 F Breast Lapatinib
8 46 F Breast Lapatinib
9 73 F Breast None
10 63 F Breast None
11 64 F Breast None 18F-FAU
12 62 F Colorectal Oxaliplatin, Bevacizumab
13 53 F Gastric None
14 49 M Colorectal Radiation
15 37 M Esophageal Oxaliplatin, Trastuzumab
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bevacizumab, lapatinib, and radiation after the second
scan (Table 1). Variable changes in tumor activity were
observed post-treatment (Table 2; Additional file 2:
Table S2). Patient 3 exhibited the largest change in SUV-
mean, with an increase of 172.3 % from baseline (Fig. 1).
Patient 4 also had a marked change in tracer retention,
with an increase in SUVmean of 89.9 % after capecitabine.
The other three patients imaged had more modest
changes in tumor SUVmean, ranging from an increase of
19.4 % to a decline of 25.4 %. Although the primary
endpoint was tracer uptake as measured by SUVmean,
the changes observed correlated with changes in SUVmax
(r2 = 0.98, P = 0.0014). Although differences in tracer flux,
calculated from compartmental-K, trended with changes
in tumor SUV (Table 2), changes in flux and SUVmean
were not correlated (r2 = 0.57, P = 0.1404).
18F-FMAU PET imaging
Five patients with breast cancer (median age: 63) were im-
aged with 18F-FMAU at baseline and following capecita-
bine treatment. Two patients received laptinib after the
start of capecitabine (Table 1). Although tumor activity
was consistently high in patients imaged with 18F-FMAU
(median SUVmean at baseline: 2.58), there was non-specific
tracer uptake throughout the lungs, which gave images a
‘grainy’ appearance (Fig. 2). Following capecitabine treat-
ment, SUVmean values ranged from an increase in 23.1 %
to a decline of 24.4 % from baseline, with an average
change of 0.2 % (Table 3; Additional file 2: Table S2).
SUVmean correlated strongly with SUVmax measurements
(r2 = 0.95, P = 0.005). As mentioned, TRR was used for
kinetic analysis in lieu of compartmental-K in patients
imaged with 18F-FMAU because the rapid clearance of
FMAU prevents the establishment of equilibrium between
tissue compartments [19]. Similarly to what was observed
in patients imaged with 18F-FLT, differences in SUVmean
and TRR after treatment trended in the same direction,
but were not strongly correlated (r2 = 0.65, P = 0.098).
18F-FAU PET imaging
Five patients (median age: 53) with breast, gastric, colo-
rectal, and esophageal junction tumors underwent 18F-
FAU PET scans at baseline and after capecitabine treat-
ment. Two patients received capecitabine alone, and the
remaining three also received treatment with either an
antibody or radiation (Table 1). The majority of the pa-
tients showed little change in tracer uptake post-
treatment (average change -10.2 %) (Table 4, Additional
file 2: Table S2). Only patient 15 displayed a notable
change in 18F-FAU retention, with a decline of 40.3 % after
capecitabine (Fig. 3). Like the previous tracers, 18F-FAU
retention was high in the kidneys and liver, but greater
non-specific tissue uptake was observed compared to
patients imaged with 18F-FLT and 18F-FMAU. In addition,
of the tracers studied, 18F-FAU had the lowest tumor
activity. As with 18F-FLT, changes in SUVmean measure-
ments correlated strongly with changes in SUVmax
(r2 = 0.98, P = 0.001). Tracer flux was calculated for 4/5
patients, with patient 11 being unevaluable due to lack
of dynamic imaging. As with the previous two tracers
studied herein, in patients imaged with 18F-FAU, tracer
flux and SUVmean were not significantly correlated
(r2 = 0.72, P = 0.1534). Furthermore, mean pretreatment
18F-FAU flux values were far lower than what was
observed with 18F-FLT (0.0059 cc/min versus
0.0251 cc/min), further underscoring the low tumor
accumulation of 18F-FAU in this patient cohort.
Discussion
Although several radiolabeled molecules have been
developed for use with PET, 2’-deoxy-2’-[18F]fluoro-D-
glucose (18F-FDG) remains the principal approved com-
pound for the detection and staging of cancer. Although
18F-FDG uptake correlates with general tumor metabol-
ism, this may not accurately describe the proliferative
capacity of cancers, which is a major consideration for
treatment and prognosis. Further, because many chemo-
therapeutics used today function by impairing cellular
proliferation, it is desirable to develop imaging modal-
ities to monitor these pathways. Accordingly, we sought
to examine the effect of capecitabine, a frequently used
anti-neoplastic compound, on the uptake and retention
of three nucleoside analogs. The goal of this study was
to gain an increased understanding of the effect of cape-
citabine on tumor thymidine metabolism, and to assess
the usefulness of these tracers in the setting of cancer
treatment.
Table 2 Tumor retention in patients imaged with 18F-FLT
Patient No. Tumor SUVmean Tracer flux into tumor (cc/min)
Baseline Post-treatment % Change Baseline Post-treatment % Change
1 1.97 1.58 −19.8 0.0271 0.0211 −22.1
2 1.96 2.34 19.4 0.0314 0.0526 67.5
3 4.70 12.80 172.3 0.0217 0.0796 266.8
4 2.27 4.31 89.9 0.0187 0.1090 482.9
5 1.34 1.00 −25.4 0.0267 0.0213 −20.2
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When evaluating changes in PET tracer accumulation,
it is important to understand the reproducibility of such
measurements in order to distinguish changes in tumor
biology from simple scan-to-scan variance. A previous
study in 9 non-small cell lung cancer patients found the
error of 18F-FLT-PET to be approximately 20 % [16].
More recently, a multi-center trial examining the repeat-
ability of PET with 18F-FDG in untreated patients found
tumor SUV to vary between a decrease of 30 % to an
increase of 40 % [40]. Although, there have been no
studies examining the repeatability of imaging with
18F-FMAU or 18F-FAU, tumor retention of these tracers is
lower than 18F-FDG, and thus, one would not expect
improved reproducibility. In our study we do not think
that the changes seen between PET scans reflect tumor
progression, since the time between baseline and post-
treatment scans ranged from 2 to 7 days. Furthermore, we
do not think that a response to treatment could cause any
clinical decline in the tumor, since the second scan was
done a day after the start of therapy with capecitabine.
Patients imaged with 18F-FLT had a variable change in
uptake after treatment, with two patients displaying a
substantial increase in tumor retention (89.9 and
172.3 %). Since 18F-FLT uptake reflects cellular TK1, the
Fig. 1 Tumor 18F-FLT Uptake in Patient 3. Axial (top) and coronal (bottom) 18F-FLT Images of a mediastinal metastasis (arrow) in a patient with
esophageal cancer at baseline (a) and after 1 day of capecitabine therapy (b). Tumor SUVmean increased from 4.70 to 12.80
Fig. 2 Tumor 18F-FMAU Uptake in Patient 7. Axial (top) and coronal (bottom) 18F-FMAU Images of a lung metastasis (arrow) in a patient with
breast cancer at baseline (a) and after 1 day of capecitabine therapy (b). Tumor SUVmean increased from 3.76 to 4.63
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large increase in SUVmean indicates an upregulation of
TK1 activity following capecitabine. This may be caused
by the inhibitory effect of 5-FU on TS [41]. As thymidine
levels drop due to TS inhibition, there is an increase in
TK1 activity as cells attempt to replenish thymidine ex-
ogenously. This increase leads to a window of 1–24 h in
which 18F-FLT uptake is significantly increased, and has
been termed the ‘flare’ phenomenon [42, 43]. This effect
has been observed in response to nucleoside analogs: 5-
FU and gemcitabine, as well as antifolates: methotrexate
and pemetrexed in preclinical models of glioma, esopha-
geal, colon, and breast cancer [41–46].
A recent study examining the flare phenomenon in
colorectal cancer patients treated with 5-FU and oxali-
platin found that 18F-FLT accumulation increased in all
patients 24 h after treatment, but increases in tumor
SUV > 45.8 % were associated with poor treatment out-
comes [47]. It is possible that a large flare may suggest
that cancers are able to successfully compensate for
drug-induced TS inhibition. Therefore, a large increase
in 18F-FLT retention may be a negative indicator of
therapy response. Conversely, the absence of change in
18F-FLT retention in the remaining three patients may
suggest that patient tumors were unable to effectively
adapt to capecitabine treatment. Alternatively, the ab-
sence of a flare could be due to upregulation of intracel-
lular TS levels leading to drug resistance, or inefficient
conversion of capecitabine to 5-FU [48].
Subjects imaged with 18F-FMAU demonstrated little
change in tracer retention after treatment. The average
change in tumor SUVmean was 0.18 % (range -24.4 to
23.1) (Table 3). Previous studies have shown increases in
18F-FMAU retention in response to oxidative, reductive,
and energy stresses due to upregulation of mitochondrial
TK2 levels [49]. Furthermore, it has been shown that
anti-cancer agents can lead to an increase in in mito-
chondrial mass during apoptosis [50, 51]. Interestingly,
patients imaged with 18F-FMAU had the highest baseline
tumor uptake: 2.58 versus 2.45 in patients scanned with
18F-FLT and 1.99 patients scanned with 18F-FAU. These
findings suggest that while tumor cells are under a high
basal level of cellular stress, this is not increased signifi-
cantly by short-term capecitabine treatment.
Similar to patients imaged with 18F-FMAU, patients
scanned with 18F-FAU demonstrated little change in tracer
retention after capecitabine (Table 4), with an average
Fig. 3 Tumor 18F-FAU Uptake in Patient 15. Axial (top) and coronal (bottom) 18F-FAU Images of a tumor of the gastroesophageal junction (arrow)
at baseline (a) and after 1 day of capecitabine therapy (b). Tumor SUVmean decreased from 3.47 to 2.07
Table 3 Tumor uptake in patients imaged with 18F-FMAU
Patient no. Tumor SUVmean Tumor retention ratio
Baseline Post-treatment % Change Baseline Post-treatment % Change
6 4.64 5.06 9.1 3.01 3.47 15.3
7 3.76 4.63 23.1 3.56 3.9 9.6
8 1.97 2.11 7.1 2.18 2.74 25.7
9 2.58 1.95 −24.4 2.03 1.65 −18.9
10 2.14 1.84 −14.0 1.22 0.96 −21.3
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change in SUVmean of -10.2 %. No difference in meas-
urement may be due to several factors, including ele-
vated tumor TS. As discussed, high tumor TS is a
common mechanism of treatment resistance in breast
and colorectal cancers [33]. In this case TS will continue to
convert FAU-P to FMAU-P, with treatment having a negli-
gible effect on this process. One patient demonstrated a
decrease of 40.3 % in tumor SUVmean from baseline in
response to capecitabine. This may be evidence of inhib-
ition of TS by capecitabine, given that TS required for re-
tention of 18F-FAU [26]. It is worth noting, however, that
tumor activity was lowest in patients imaged with 18F-FAU,
suggesting a low level of tumor specificity for this tracer.
Major limitations of this study included small sample
sizes and heterogenous patient cohorts. Patients enrolled
in this study had several different malignancies and
received varied treatment regimens (Table 1 and Additional
file 1: Table S1). The duration of capecitabine treat-
ment after the second PET scan was inconsistent be-
tween individuals and the majority of subjects (9 of
15) were administered other anti-neoplastic therapy in
addition to capecitabine. For these reasons, we are
unable to correlate our imaging findings to patient re-
sponse to capecitabine and therefore our results
should be considered observational.
Conclusions
In this exploratory study, we sought to monitor the
response of patient tumors to capecitabine, a commonly
used chemotherapeutic, using three experimental imaging
tracers: 18F-FLT, 18F-FMAU, and 18F-FAU. Patients who
underwent PET with 18F-FAU and 18F-FMAU showed little
change, on average, after treatment. However, in-line with
similar studies, we observed that patients treated with
capecitabine can produce a marked increase in 18F-FLT
retention in some patients. Further studies are warranted
to determine if this effect could be used as an early
biomarker for therapeutic efficacy.
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